Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9188MR)

This product GTTS-WQ9188MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9188MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10093MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ972MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ15204MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ1062MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ14085MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ11509MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ15272MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ1455MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW